Anhui Huaren Health Pharmaceutical Co., Ltd. Class A

Anhui Huaren Health Pharmaceutical Co., Ltd. Class A

SSZSE:301408
12.76
CNY
-0.39
(-2.97%)
0.69EPS
23.87P/E
5.97BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.97B, placing it among publicly traded companies globally. Its enterprise value stands at 6.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.97B
Enterprise Value6.20B

Share Statistics

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A has 400.01M shares outstanding.

Shares Outstanding400.01M

Valuation Ratios

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 23.87. The price-to-sales ratio is 1.01, and the price-to-book ratio stands at 2.72.

PE Ratio23.87
PS Ratio1.01
PB Ratio2.72
P/TBV Ratio7.51

Enterprise Valuation

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 16.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.20B versus a market cap of 5.97B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.05
EV / EBITDA16.00
EV / EBIT16.00

Financial Position

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.67, indicating elevated leverage, while an interest coverage ratio of 12.12 demonstrates strong ability to service its debt obligations.

Current Ratio1.07
Quick Ratio0.46
Debt / Equity74.67
Debt / EBITDA4.36
Interest Coverage12.12

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 661,103.63 in revenue per employee across its workforce of 8,938.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee661,103.63
Employee Count8,938.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A recorded 107.70M in income tax expense. That works out to an effective tax rate of 28.13, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 382.80M, leaving 250.17M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax107.70M
Effective Tax Rate28.13

Stock Price Statistics

CNY

As of the close on November 17, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A's stock has declined approximately 19.95% over the past 52 weeks. The 50-day moving average sits at 14.24, while the 200-day moving average is 16.83.

52-Week Price Change-19.95%
50-Day Moving Average14.24
200-Day Moving Average16.83

Income Statement

CNY

Over the twelve months ended September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A generated 5.91B in revenue and converted that into 250.17M in net income, yielding earnings per share of 0.69. EBITDA reached 387.40M, while operating income came in at 499.22M.

Revenue5.91B
Gross Profit2.05B
Operating Income499.22M
Pretax Income382.80M
Net Income250.17M
EBITDA387.40M
EBIT387.40M
Earnings Per Share (EPS)0.69

Balance Sheet

CNY

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A holds 1.52B in cash and equivalents against 1.69B in total debt, resulting in a net debt position of -264.31M. Total book value stands at 2.20B, with working capital of 216.79M providing operational flexibility.

Cash & Cash Equivalents1.52B
Total Debt1.69B
Net Debt-264.31M
Equity (Book Value)2.20B
Book Value Per Share5.50
Working Capital216.79M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-135.40M

Margins

Over the twelve months ended September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A posted a gross margin of 34.70, reflecting its pricing power and cost economics. The operating margin of 8.45 and net profit margin of 4.23 provide insight into operational efficiency.

Gross Margin34.70
Operating Margin8.45
Pretax Margin6.48
Profit Margin4.23
EBITDA Margin6.56

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of 20.49 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 9.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Anhui Huaren Health Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.15
Payout Ratio20.49
Shareholder Yield9.22

Scores

As of September 30, 2026, Anhui Huaren Health Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 2.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.83